Introduction
Protein kinases catalyze the transfer of the y-phosphate from ATP to serine, threonine, tyrosine or histidine residues of protein substrates. They play a central role in controlling many signal transduction pathways including those in B and T cells of the immune system and neurons in the brain [l-4] . In fact, all eukaryotic cells contain many protein kinase regulatory systems (it is estimated that 2% of the human genome encodes protein kinases [5] ). Because of the enormous size of the protein kinase family, the tremendous redundancy and overlapping substrate specificities of many protein kinases, the dissection of kinase signaling pathways is a challenge to existing genetic and biochemical techniques [6] . For example, kinase gene-knockouts often show no phenotype because other cellular kinases compensate for the missing kinase activity [7-91. One approach' that avoids the problems associated with gene compensation is the development of mono-specific small-molecule inhibitors of engineered kinases [lO,ll] . Such inhibitors could be used to selectively block kinase function in order to map pathways. Kinase inhibitors are also potential therapeutics, but tremendous effort is required to identify compounds that can selectively bind to one particular kinase out of the estimated 2000 highly homologous human protein kinases [ 1 Z-141.
One simplifying approach is to develop 'family-selective' protein kinase inhibitors that can potently inhibit all highly homologous members of a protein kinase family. The sequence identity of the kinase catalytic domains is high for kinases within a family (70~85% within Src family members), but is smaller between families (-20% between c-Src and protein kinase A Two key problems remain with the use of PPl as a tool for deconvoluting Src family dependent cell signaling pathways. First, PPl shows little specificity between Src family kinases and therefore cannot be used to dissect the role of individual Src family kinases that are coexpressed in a given cell (e.g. T cells, B cells, mast cells and dendritic cells). Second, the assertion that PPl is truly Src family selective has not been rigorously tested.
The problem of rigorously checking whether a given kinase inhibitor can inhibit other ('off-target') kinases in the organism of interest is common to all kinase inhibitors. The reason for this is that not all human protein kinases have been identified. Furthermore, the task of expressing, purifying and assaying anything close to all human kinases (-2000 ) is an almost impossible task. New sequence homology based methods coupled to high-throughput screening for kinase inhibitors might obviate the need to screen against all naturally occurring protein kinases [33] . Yet without such structure-activity data the use of small-molecule inhibitors in cell-signaling studies may be misleading. To address this problem we have identified the key binding site amino acid residue responsible for imparting selective kinase inhibition of PPl. Through systematic mutagenesis of Ile338 in v-Src, as well as the non-Src family kinases cAbl, CaMKIIa, Cdk2 and ~38, we have found a strong correlation between PPl binding affinity and amino acid sidechain volume at the position corresponding to Ile338 in v-Src. We used this sequence information to identify another non-Src family kinase (c-Abl) that is potently inhibited by PPl. This study shows that a large component of PPl selectivity results from residue 338 and that other protein kinases can be analyzed in the same way to reveal the potential for inhibition by PPl.
Results and discussion
Molecular modeling of PPl binding to Hck and comparison with kinase sequence alignments As reported by Hanke etal. [24] PPl is a potent inhibitor of Lck (IC,, = 0.005 l.tM) and Fyn (IC,, = 0.006 PM), but is much less potent for ZAP-70 (IC,, z 100 PM) and JAKZ (IC,, > 50 pM; Table 1 ). To date, the crystal structure of PPl bound to a kinase has not been solved. We therefore used the co-crystal structure of the Src family kinase Hck bound to the general kinase inhibitor quercetin and a nonhydrolyzable ATP analog AMP-PNP as a guide to dock PPl into the ATP-binding site of Hck (Figure la-d) [34] . From this predicted binding mode, the C3 phenyl ring is in close contact with the sidechain of residue Thr338. This proximity of the C3 phenyl ring and the Thr338 sidechain suggested to us that this residue could be a key determinant for PPl binding to Src family kinases.
The position adjacent to C3, the N4 exocyclic amine of PPl, has already been shown to be in close contact with Ile338. This binding mode was confirmed through synthesis of PPl analogs with substituents at the N4 position, and design of compensatory mutations (Ile338+Ala or Ile338+Gly) in v-Src [lo] . When a bulky group such as (p-tert-butyl) benzoyl is added to the N4 amine of PPl, this PPl analog does not inhibit wild-type Src family kinases (IC,, > 300 pM for wild-type v-Src and wild-type Fyn) and it inhibits the Ile338+Gly v-Src mutant (IC,, = 0.43 PM) and Thr339+Gly Fyn mutant (IC,, = 0.83 pM) potently. Further molecular modeling suggested that the C3 phenyl ring adjacent to N4 amine of PPl is also in close contact Most Ser/Thr kinases have larger hydrophobic residues (Met, Phe, Leu and Gln) at the position corresponding to Thr338 in the Src family kinases (Figure 2 ). From a simple docking analysis it appears that such large amino acid sidechains would sterically clash with the phenyl ring in PPl ( Figure Id) . We predicted that PPl does not inhibit Ser/Thr kinases because these kinases contain a larger residue than threonine at the position corresponding to 338 in c-Src. Sequence alignments of the nine members of the Src family tyrosine kinases support this idea in that they all have a threonine at position 338 ( Figure 2 ). In contrast, each of the noninhibited kinases reported by Hanke et al [24] , ZAP-70, JAKZ and PKA, all have a methionine at this position ( Figure 2 ). On the basis of this analysis we propose that the position corresponding to Thr338 in Hck controls the binding of PPl to other kinases. Non-Src family kinases that have a threonine at the position corresponding to 338 in the Src family, such as c-Abl, PDGFR and ~38, could also be potently inhibited by PPl.
Effect of position 338 amino acid identity on PPl inhibition
The first experimental evidence that PPl derived its ability to inhibit Src family kinases because this family of kinases shared a threonine residue at position 338 (Src numbering will be used throughout) came from the discovery that PPl was a 700 nM inhibitor of c-Src and yet was a poor (IC,, = 5 pM) inhibitor of the almost identical oncogenic protein v&c. v-Src and c-Src are almost identical in their catalytic domains (98% identical). The only amino acid substitution in v&c that maps to the active site is a Thr338+Ile substitution. As we found that PPl is not a potent inhibitor for v-Src (Ile338) but is potent against c-Src (Thr338), it suggested to us that the modest Thr+Ile mutation at position 338 might be essential for potent PPl inhibition.
To more carefully test the relationship between residue 338 and PPI potency, we mutated Ile338 in v-Src to eight different amino acids (Phe, Met, Thr, Val, Cys, Ser, Ala and Gly). A truncated form of v-Src that contains the catalytic domain of v-Src, but no functional SH3 or SHZ domains (XD4) was used as the model kinase in this study because it can be expressed in Eschetichia co& whereas other Src family kinases must be expressed in Sf9 insect cells. The XD4 fragment was fused to glutathione S-transferase (GST), which has been shown to aid in expression of protein kinases in bacteria [35, 36] . The dimeric state of GST itself does not interfere with protein kinase activity as the GST-fused kinase exhibits the same kinetic constants as v-Src without the GST fusion [37] . When Ile338 was mutated to larger residues (phenylalanine and methionine), these v-Src mutants, Ile338+Phe XD4 and Ile338-+Met XD4, were poorly inhibited by PPl (IC,, = 8 pM for both mutants). The percent activity of Ile338+Met and Ile338-+Phe XD4 mutants are about 25% and 10% of that of wild-type XD4, respectively (Table Z) , and are comparable with the activity of Ile338+Thr mutant. It is surprising that position 338 can tolerate almost any sized sidechain, without complete loss of catalytic activity. On the basis of these results with v-Src, we expect that the Thr338+Phe or Thr338+Met mutants of c-Src could potentially be useful in studies where a PPl insensitive c-Src (or other Src family kinase) is needed.
Is a small residue at position 338 sufficient to confer PPl inhibition?
To test whether a small amino acid at position 338 is sufficient for potent PPl inhibition, we mutated Ile338 to threonine, serine, alanine and glycine in XD4. The IC,, value of Ile338-+Thr XD4 (100 nM) is 50 times lower than the wild-type XD4. The smaller substitution (Ile338-+Ser) afforded a more poorly inhibited kinase (IC,, = 0.4 PM), perhaps because of the hydrophilic character of serine compared with threonine and the predicted preference of the C3 phenyl ring to bind in a hydrophobic pocket. The most potently inhibited v-Src mutants contained the smallest naturally occurring residues, alanine and glycine (IC,, = 0.005 l.tM for Ile338+Ala and Ile338+Gly mutants). Mutation of Ile338 to alanine therefore results in lOOO-fold more potent kinase inhibition by PPl. To test the generality of this mutation in other Src family kinases, we also mutated Thr339 (corresponding to Ile338 in v-Src) in Fyn to alanine. PPl inhibits wild-type Fyn with an IC,, of 0.05 yM, and is tenfold more potent against Thr338+Ala Fyn (IC,, = 0.005 PM).
On the basis of the structure-activity relationships of PPl with v-Src and Fyn mutants at position 338, we conclude that PPl is Src family selective because all cellular Src family members have a threonine at position 338. Based on this analysis we asked if other kinases might be inhibited by PPl that have not been reported. We reasoned that PPl might effectively (I& < 1.0 pM) inhibit non-Src family tyrosine kinases that have a threonine at the position corresponding to 338 in c-Src. The tyrosine kinase c-Abl has a threonine at position 334 (corresponding to 338 in v-Src; Figure 2 ). We used a truncated c-Abl containing only the intact SHZ and SHl domains that is active when expressed in E. coli [38] and determined that PPl inhibits the non-Src family kinase, c-Abl, with an IC,, of 0.3 PM. Compared with the Ile338+Thr v-Src mutant (IC,, = 0.1 l.tM) and wild-type Fyn (IC,, = 0.05 PM), PPl is only threefold less potent against the non-& family kinase c-Abl. The finding that a non-Src family kinase, c-Abl (50% identical to Src family kinases) can be inhibited by PPl, purely based on a sequence alignment comparison of one residue in the kinase binding site, confirms that residue 338 is essential for PPl binding to protein kinases. Furthermore, PPl may exhibit similar binding affinities for kinases with very divergent sequences from the Src family yet which contain a threonine or serine at the position corresponding to position 338 in c-Src (such as PDGFRcx&P, c-kit, Csk and ~38; Figure 2 ).
Mutation of position 338 to alanine or glycine to sensitize Ser/Thr kinases to PPl inhibition
To test the possibility that PPl could inhibit members of the Ser/Thr kinase family of enzymes if they contained a small residue at position 338 we mutated several highly divergent kinases to contain an alanine or glycine at this position. The Ser/Thr kinases in general have a large hydrophobic residue at the site corresponding to position 338 in c-Src. This fact suggests that PPl will not be a very effective inhibitor of these kinases. Furthermore, there may be other amino acid differences responsible for poor inhibition by PPl. We tested this using the Ser/Thr kinase Caz+/calmodulin dependent kinaseIIa (CamKIIa) and cyclin-dependent kinase 2 (Cdk2). CamKII regulates diverse cellular processes, including neurotransmitter release, muscle contraction, gene expression and cell proliferation [39] . CdkZ is an important regulator of the timing and co-ordination of eukaryotic cell-cycle events [40] . Both CamKIItx and Cdk2 have a phenylalanine at the position (Phe89 in CamKIIa and Phe80 in Cdk2) corresponding to Ile338 in v-Src. We expressed CamKIIcr as a GST fusion protein in E. coli and expressed Cdk2 in insect cells. PPl shows very poor inhibition of wild-type CamKIIa (IC,, = 60 PM) and wild-type Cdk2 (IC,, = 50 PM) as predicted on the basis of the requirement for a small sidechain at position 338. When Phe89 is mutated to alanine, the Phe89+Ala CamKIIa possessed an IC,, = 10 l.tM for PPl. When Phe89 is further mutated to glycine, the mutant displays an inhibition IC,, = 0.5 PM, only S-lo-fold lower than inhibition of wild-type Src family kinases. The Phe80+Gly Cdk2 mutant is even more potently inhibited (IC,, = 0.16 yM), representing a > 300-fold improvement in PPl inhibition.
Although most Ser/Thr kinases have a larger residue than threonine at the position corresponding to Ile338 in v-Src, a mitogen-activated protein kinase (MAPK), ~38, contains a threonine at this position (Thr106). Thr106 in ~38 has already been shown to control the sensitivity of a MAP kinase inhibitor SB203580 [41] [42] [43] . SB203580 potently inhibits MAP kinases that have a threonine at position 106 such as ~38, and poorly inhibits those with a residue larger 
GST-CamKII Although Ser/Thr kinases share less than 20% sequence identity with tyrosine kinases throughout the catalytic domains, they share high homology in the region directly surrounding the ATP-binding site, where the ATP-competitive inhibitors bind. This is most clearly demonstrated by the bis-indolemaleimide natural product staurosporine which is a potent (IC,, -10 nm) but nonselective protein kinase inhibitor [45] . Similarly, the flavone, quercetin is a general tyrosine kinase inhibitor (IC,, -24 PM) that also inhibits protein kinase C (IC,, -31 yM) [46] . For selective kinase inhibitors such as PPl, it is important to determine the residues that control binding to different kinases and to determine whether the sequence determinants are highly context dependent. Mutagenesis of homologous residues in widely varying kinases might provide a way to determine these rules without the need to clone and express each member of the kinase superfamily. Clearly, more residues in addition to position corresponding to He338 in v-&c contribute to PPl binding. These features could be uncovered by saturation mutagenesis of the active-site residues as well as determination of the crystal structure of PPl bound to a Src family kinase.
Significance kinases using molecular modeling and seauence analvsis. 
